News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Results of the NICHE-2 study by Myriam Chalabi – The Netherlands Cancer Institute
Photo from The Netherlands Cancer Institute/X
Jun 7, 2024, 09:11

Results of the NICHE-2 study by Myriam Chalabi – The Netherlands Cancer Institute

The Netherlands Cancer Institute (NKI) shared on X:

“More success for neoadjuvant immunotherapy: results of the NICHE-2 study by Myriam Chalabi show that it is highly effective in a subset of patients with colon cancer.

In 68% of patients there were no live cancer cells.”

Source: The Netherlands Cancer Institute/X

 

cancer Myriam Chalabi NICHE-2 OncoDaily Oncology
Special Coverage
Blog
Mar 30, 2025, 18:31
Matthew Kurian: Happy Doctors’ Day to all the incredible physicians
Blog
Mar 30, 2025, 18:26
Indiana’s first mobile lung screening program is officially on the road - IU Simon Comprehensive Cancer Center
Blog
Mar 30, 2025, 18:14
Join the Richard and Alice Bucher Emerald Circle and help create a world without pediatric cancers - St. Baldrick's Foundation
Blog
Mar 30, 2025, 18:01
Philippe Spiess: Always an honor to deliver an update in the management of bladder cancer with Tom Flaig
Blog
Mar 30, 2025, 17:46
Thought-provoking trial on localized pancreatic cancer presented by Ethan Agritelley at SSO2025 - Duke Surgical Oncology
Blog
Mar 30, 2025, 17:44
Addressing Gaps in Awareness, Care, and Support for the Early-Age Onset Digestive Cancer Community - European Cancer Organisation
Blog
Mar 30, 2025, 17:34
Olga Kantor: Fantastic presentation by Monika Masanam on MIBC after NST at SSO2025
Blog
Mar 30, 2025, 17:19
Carlos Ayala-Navarro on the immune microenvironment in appendiceal cancers - Moffitt Cancer Center
Blog
Mar 30, 2025, 17:19
Roupen Odabashian: Comparing Research Compensation - Healthcare vs AI
Blog
Mar 30, 2025, 17:05
Julien Mazieres: Heterogeneity of resistance mechanisms should lead to a personalized strategy
Blog
Mar 30, 2025, 16:56
Joe Chang: Optimal first-line treatment for EGFR-mutated mNSCLC
Positive
Mar 30, 2025, 16:44
Yüksel Ürün: FDA approves neoadjuvant and adjuvant durvalumab in MIBC